RU2017101436A - Mic-1 слитные белки и их применение - Google Patents
Mic-1 слитные белки и их применение Download PDFInfo
- Publication number
- RU2017101436A RU2017101436A RU2017101436A RU2017101436A RU2017101436A RU 2017101436 A RU2017101436 A RU 2017101436A RU 2017101436 A RU2017101436 A RU 2017101436A RU 2017101436 A RU2017101436 A RU 2017101436A RU 2017101436 A RU2017101436 A RU 2017101436A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- mic
- compound according
- peptide linker
- serum albumin
- Prior art date
Links
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 title claims 9
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 title claims 9
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000008100 Human Serum Albumin Human genes 0.000 claims 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims 8
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 102000046181 human GDF15 Human genes 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 238000010396 two-hybrid screening Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14173664 | 2014-06-24 | ||
| EP14173664.5 | 2014-06-24 | ||
| PCT/EP2015/063596 WO2015197446A1 (en) | 2014-06-24 | 2015-06-17 | Mic-1 fusion proteins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017101436A true RU2017101436A (ru) | 2018-07-24 |
| RU2017101436A3 RU2017101436A3 (OSRAM) | 2019-02-13 |
Family
ID=51032955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017101436A RU2017101436A (ru) | 2014-06-24 | 2015-06-17 | Mic-1 слитные белки и их применение |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9272019B2 (OSRAM) |
| EP (1) | EP3160496B1 (OSRAM) |
| JP (1) | JP6696915B2 (OSRAM) |
| KR (1) | KR20170020383A (OSRAM) |
| CN (1) | CN106459222A (OSRAM) |
| AR (1) | AR100945A1 (OSRAM) |
| AU (1) | AU2015279525A1 (OSRAM) |
| BR (1) | BR112016029848A2 (OSRAM) |
| CA (1) | CA2952293A1 (OSRAM) |
| IL (1) | IL249327A0 (OSRAM) |
| MX (1) | MX2016016063A (OSRAM) |
| RU (1) | RU2017101436A (OSRAM) |
| TW (1) | TW201613958A (OSRAM) |
| WO (1) | WO2015197446A1 (OSRAM) |
| ZA (1) | ZA201608214B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX343729B (es) | 2011-04-08 | 2016-11-18 | Amgen Inc | Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos. |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
| PE20190117A1 (es) * | 2016-05-24 | 2019-01-16 | Novo Nordisk As | Compuestos de mic-1 y usos de estos |
| GB201615844D0 (en) * | 2016-09-16 | 2016-11-02 | Genagon Therapeutics Ab | Agents for use in therapy |
| CA3045700A1 (en) | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
| GB201700567D0 (en) | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| GB201700553D0 (en) * | 2017-01-12 | 2017-03-01 | Genagon Therapeutics Ab | Therapeutic agents |
| WO2018193033A1 (en) | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| MA50233A (fr) | 2017-09-10 | 2020-07-22 | Novo Nordisk As | Mic-1 et glp-1 destinés à être utilisés dans le traitement de l'obésité |
| JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 糖タンパク質の製造 |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| KR20200140878A (ko) | 2018-04-09 | 2020-12-16 | 암젠 인크 | 성장 분화 인자 15 융합 단백질 |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| KR20210044244A (ko) | 2018-08-10 | 2021-04-22 | 노파르티스 아게 | Gfral 세포외 도메인 및 사용 방법 |
| CR20210193A (es) | 2018-10-22 | 2021-06-15 | Janssen Pharmaceutica Nv | Proteínas de fusión de péptido similar al glucagón 1 (glp1)-factor de diferenciación de crecimiento 15 (gdf15) y usos de estas |
| US20230210950A1 (en) | 2019-10-04 | 2023-07-06 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| AU2020394255A1 (en) * | 2019-11-26 | 2022-06-09 | Yuhan Corporation | Long-acting GDF15 fusion protein and pharmaceutical composition comprising same |
| US12433938B2 (en) * | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| BR112022011540A2 (pt) * | 2019-12-11 | 2022-09-06 | Lg Chemical Ltd | Polipeptídeo de fusão compreendendo gdf15, composição farmacêutica que compreende o mesmo, dímero e método de preparação do dito polipeptídeo, método para aumentar a estabilidade in vivo de gdf15, molécula de ácido nucleico, vetor e célula recombinantes e uso terapêutico do dito polipeptídeo e dímero |
| WO2021133822A1 (en) * | 2019-12-24 | 2021-07-01 | Juvena Therapeutics,Inc. | Regenerative polypeptides and uses thereof |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021194257A1 (ko) * | 2020-03-25 | 2021-09-30 | (주) 업테라 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| KR102195740B1 (ko) * | 2020-03-25 | 2020-12-28 | 서울대학교산학협력단 | 세포 투과성 펩티드 이량체, 이의 제조방법 및 이를 이용한 카고 전달 시스템 |
| CN115244076B (zh) | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
| CN112694520B (zh) * | 2020-12-02 | 2023-01-17 | 图凌(杭州)生物医药有限公司 | 一种人工多肽hm、其抗体及在病理检测中的应用 |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4476212A1 (en) | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
| ES2555956T3 (es) | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| US7576190B2 (en) * | 2004-05-13 | 2009-08-18 | Eli Lilly And Company | FGF-21 fusion proteins |
| US20090221477A1 (en) * | 2004-07-26 | 2009-09-03 | Asterion Limited | Linkers |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| MX2014009129A (es) * | 2012-01-26 | 2014-11-21 | Amgen Inc | Polipeptidos de factor 15 de diferenciacion de crecimiento (gdf-15). |
| EP2830646B1 (en) * | 2012-03-27 | 2018-03-07 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9828415B2 (en) | 2013-01-30 | 2017-11-28 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
-
2015
- 2015-06-17 WO PCT/EP2015/063596 patent/WO2015197446A1/en not_active Ceased
- 2015-06-17 CA CA2952293A patent/CA2952293A1/en not_active Withdrawn
- 2015-06-17 CN CN201580033507.XA patent/CN106459222A/zh not_active Withdrawn
- 2015-06-17 US US14/742,159 patent/US9272019B2/en not_active Expired - Fee Related
- 2015-06-17 KR KR1020167037059A patent/KR20170020383A/ko not_active Withdrawn
- 2015-06-17 MX MX2016016063A patent/MX2016016063A/es unknown
- 2015-06-17 EP EP15730140.9A patent/EP3160496B1/en not_active Withdrawn - After Issue
- 2015-06-17 BR BR112016029848A patent/BR112016029848A2/pt not_active Application Discontinuation
- 2015-06-17 JP JP2016574944A patent/JP6696915B2/ja not_active Expired - Fee Related
- 2015-06-17 TW TW104119532A patent/TW201613958A/zh unknown
- 2015-06-17 AU AU2015279525A patent/AU2015279525A1/en not_active Withdrawn
- 2015-06-17 RU RU2017101436A patent/RU2017101436A/ru unknown
- 2015-06-23 AR ARP150102007A patent/AR100945A1/es active IP Right Grant
-
2016
- 2016-01-19 US US15/000,637 patent/US9956264B2/en not_active Expired - Fee Related
- 2016-11-28 ZA ZA2016/08214A patent/ZA201608214B/en unknown
- 2016-12-01 IL IL249327A patent/IL249327A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL249327A0 (en) | 2017-02-28 |
| ZA201608214B (en) | 2018-11-28 |
| CN106459222A (zh) | 2017-02-22 |
| KR20170020383A (ko) | 2017-02-22 |
| WO2015197446A1 (en) | 2015-12-30 |
| AU2015279525A1 (en) | 2016-12-15 |
| US9272019B2 (en) | 2016-03-01 |
| TW201613958A (en) | 2016-04-16 |
| US9956264B2 (en) | 2018-05-01 |
| RU2017101436A3 (OSRAM) | 2019-02-13 |
| CA2952293A1 (en) | 2015-12-30 |
| JP2017528419A (ja) | 2017-09-28 |
| MX2016016063A (es) | 2017-03-10 |
| US20160015784A1 (en) | 2016-01-21 |
| EP3160496A1 (en) | 2017-05-03 |
| US20160129083A1 (en) | 2016-05-12 |
| AR100945A1 (es) | 2016-11-09 |
| EP3160496B1 (en) | 2021-03-03 |
| JP6696915B2 (ja) | 2020-05-20 |
| BR112016029848A2 (pt) | 2017-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| JP2017528419A5 (OSRAM) | ||
| Takahashi et al. | Structural determinants of host defense peptides for antimicrobial activity and target cell selectivity | |
| JP2014040483A5 (OSRAM) | ||
| ATE517119T1 (de) | Einzelketteninsulin | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| JP2017523789A5 (OSRAM) | ||
| JP2015525217A5 (OSRAM) | ||
| JP2019013251A5 (OSRAM) | ||
| EA201100038A1 (ru) | Коагонисты глюкагонового рецептора/glp-1-рецептора | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| JP2016512213A5 (OSRAM) | ||
| EA202090577A2 (ru) | Соматотропный гормон пролонгированного действия и способы его получения | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| RU2010122053A (ru) | Иммуносупрессорные полипептиды и нуклеиновые кислоты | |
| JP2014224126A5 (OSRAM) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| CY1119976T1 (el) | Μιμητικα καλσιτονινης για την αντιμετωπιση ασθενειων και διαταραχων | |
| RU2016145061A (ru) | Профилактическая вакцина против синдрома падения яйценоскости (eds) | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| RU2017125050A (ru) | Производные fgf21 и их применения | |
| JP2019533722A5 (OSRAM) | ||
| JP2016516734A5 (OSRAM) | ||
| JP2015524403A5 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20190904 |